Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging.

[1]  H. Dralle,et al.  Benefit-Risk Balance of Reoperation for Persistent Medullary Thyroid Cancer , 2013, Annals of surgery.

[2]  H. Dralle,et al.  Prognostic Impact of N Staging in 715 Medullary Thyroid Cancer Patients: Proposal for a Revised Staging System , 2013, Annals of surgery.

[3]  R. Tuttle,et al.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.

[4]  R. Tuttle,et al.  In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. , 2011, Thyroid : official journal of the American Thyroid Association.

[5]  A. Gawande,et al.  Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. , 2011, Surgery.

[6]  G. Cevenini,et al.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.

[7]  A. Gill,et al.  MicroRNA Profiling of Sporadic and Hereditary Medullary Thyroid Cancer Identifies Predictors of Nodal Metastasis, Prognosis, and Potential Therapeutic Targets , 2011, Clinical Cancer Research.

[8]  G. Agarwal,et al.  Medullary Thyroid Cancer: Clinico-pathological Profile and Outcome in a Tertiary Care Center in North India , 2011, World Journal of Surgery.

[9]  N. Morgenthaler,et al.  Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. , 2011, Clinical chemistry.

[10]  A. Dackiw,et al.  Survival Implications of Cervical Lymphadenectomy in Patients with Medullary Thyroid Cancer , 2011, Annals of Surgical Oncology.

[11]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[12]  E. Gubała,et al.  The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report , 2010, Thyroid research.

[13]  H. Dralle,et al.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[14]  S. le Cessie,et al.  Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta‐analysis , 2010, Clinical endocrinology.

[15]  P. Parrilla,et al.  Prognostic Value of Histological and Immunohistochemical Characteristics for Predicting the Recurrence of Medullary Thyroid Carcinoma , 2010, Annals of Surgical Oncology.

[16]  S. Roman,et al.  Medullary Thyroid Cancer: Are Practice Patterns in the United States Discordant From American Thyroid Association Guidelines? , 2010, Annals of Surgical Oncology.

[17]  Kwang-Yoon Jung,et al.  Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. , 2010, Thyroid : official journal of the American Thyroid Association.

[18]  M. Walter,et al.  Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer , 2009, Cancer.

[19]  A. Chou,et al.  Medullary Thyroid Carcinoma: Long-Term Outcomes of Surgical Treatment , 2010, Annals of Surgical Oncology.

[20]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[21]  L. Ward,et al.  Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. , 2009, Arquivos brasileiros de endocrinologia e metabologia.

[22]  A. Miyauchi,et al.  Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastasis to the lateral compartment. , 2009, Endocrine journal.

[23]  L. Brandão,et al.  Prognostic Influence of Clinical and Pathological Factors in Medullary Thyroid Carcinoma: A Study of 53 Cases , 2009, Clinics.

[24]  D. Farley,et al.  Need for a revised staging consensus in medullary thyroid carcinoma. , 2009, Archives of surgery.

[25]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[26]  Mark Dowar,et al.  Influence of age and primary tumor size on the risk for residual/recurrent well‐differentiated thyroid carcinoma , 2009, Head & neck.

[27]  A. Algeciras-Schimnich,et al.  Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[28]  Tuttle Rm.  Risk-Adapted Management of Thyroid Cancer , 2008 .

[29]  C. Pirich,et al.  Long‐term prognosis of medullary thyroid carcinoma , 2008, Clinical endocrinology.

[30]  S. Roman,et al.  Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. , 2008, Thyroid : official journal of the American Thyroid Association.

[31]  J. Vieira,et al.  Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. , 2008, Thyroid : official journal of the American Thyroid Association.

[32]  B. Nilsson,et al.  Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma? , 2008, Langenbeck's Archives of Surgery.

[33]  P. Schneider,et al.  Prognostic Value of Lymph Node Yield and Metastatic Lymph Node Ratio in Medullary Thyroid Carcinoma , 2008, Annals of Surgical Oncology.

[34]  E. Baudin,et al.  Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. , 2008, European journal of endocrinology.

[35]  A. Miyauchi,et al.  Alternative Surgical Strategies and Favorable Outcomes in Patients with Medullary Thyroid Carcinoma in Japan: Experience of a Single Institution , 2008, World Journal of Surgery.

[36]  C. Stratakis,et al.  Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. , 2008, Histology and histopathology.

[37]  C. Eisenberger,et al.  Long-Term Clinical and Biochemical Follow-up in Medullary Thyroid Carcinoma: A Single Institution's Experience Over 20 Years , 2007, Annals of surgery.

[38]  S. Hauptmann,et al.  Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. , 2007, Archives of surgery.

[39]  S. Roman,et al.  Prognosis of medullary thyroid carcinoma , 2006, Cancer.

[40]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[41]  J. Soga,et al.  Dedifferentiation of neoplastic cells in medullary thyroid carcinoma: Report of a case , 1999, Surgery Today.

[42]  F. Kraeber-Bodéré,et al.  Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.

[43]  E. Baudin,et al.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. , 2005, The Journal of clinical endocrinology and metabolism.

[44]  Jonathan R. Clark,et al.  Prognostic Variables and Calcitonin in Medullary Thyroid Cancer , 2005, The Laryngoscope.

[45]  H. Holzhausen,et al.  Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. , 2005, The Journal of clinical endocrinology and metabolism.

[46]  H. Dralle,et al.  Single Center Experience in Primary Surgery for Medullary Thyroid Carcinoma , 2004, World Journal of Surgery.

[47]  K. Kameyama,et al.  Medullary thyroid carcinoma: nationwide Japanese survey of 634 cases in 1996 and 271 cases in 2002. , 2004, Endocrine journal.

[48]  E. Baudin,et al.  Medullary Thyroid Carcinoma , 2016 .

[49]  S. Ismailov,et al.  Postoperative calcitonin study in medullary thyroid carcinoma. , 2004, Endocrine-related cancer.

[50]  A. Pinchera,et al.  Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. , 2004, The Journal of clinical endocrinology and metabolism.

[51]  K. Becker,et al.  Calcitonin precursor levels in human medullary thyroid carcinoma. , 2003, Thyroid : official journal of the American Thyroid Association.

[52]  E. Baudin,et al.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging , 2003, British Journal of Cancer.

[53]  E. Baudin,et al.  Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. , 2003, The Journal of clinical endocrinology and metabolism.

[54]  T. Schilling,et al.  Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. , 2001, Surgery.

[55]  S. Bardet,et al.  Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma , 2001, Clinical endocrinology.

[56]  R. Hinze,et al.  Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis , 2000, Cancer.

[57]  Q. Duh,et al.  Medullary thyroid carcinoma , 2000, Cancer.

[58]  H. Heshmati,et al.  Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). , 2000, The Journal of clinical endocrinology and metabolism.

[59]  J. Moley,et al.  Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. , 1999, Annals of surgery.

[60]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[61]  H. Dralle,et al.  Determinative Factors of Biochemical Cure after Primary and Reoperative Surgery for Sporadic Medullary Thyroid Carcinoma , 1998, World Journal of Surgery.

[62]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .

[63]  M. Dottorini,et al.  Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  R. Bergström,et al.  Long term follow‐up of patients with medullary carcinoma of the thyroid , 1997, Cancer.

[65]  P. Bernante,et al.  Prognostic Value of Early Postoperative Calcitonin Level in Medullary Thyroid Carcinoma , 1994, Tumori.

[66]  H. Gharib,et al.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. , 1990, Annals of surgery.

[67]  M. Saad,et al.  Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. , 1984, The Journal of clinical endocrinology and metabolism.

[68]  A. Miyauchi,et al.  Relation of Doubling Time of Plasma Calcitonin Levels to Prognosis and Recurrence of Medullary Thyroid Carcinoma , 1984, Annals of surgery.

[69]  N. Samaan,et al.  Medullary thyroid carcinoma. Importance of serial serum calcitonin measurement , 1979, Cancer.

[70]  N. Samaan,et al.  MEDULLARY (SOLID) CARCINOMA OF THE THYROID GLAND: AN ANALYSIS OF THE M. D. ANDERSON HOSPITAL EXPERIENCE WITH PATIENTS WITH THE TUMOR, ITS SPECIAL FEATURES, AND ITS HISTOGENESIS , 1973, Medicine.